TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7834990
Drug: D‐aldosterone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐aldosterone infusion
Study: 3165298
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b (IFN alpha-2b) administered three times a week at doses of 2 or 5 X 10(6) IU/m2 for chronic phase patients; 5 X 10(6) IU/m2 for accelerated phase patients.
Study: 3165298
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of Interferon alpha-2b (IFN alpha-2b) at doses from 2 to 5 X 10(6) IU/m2.
Study: 3165298
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b (IFN alpha-2b) treatment.
Study: 23485864
Drug: Saline/GHRP-2 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline/GHRP-2 infusion
Study: 10839492
Drug: Neoadjuvant chemotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy, concomitant chemotherapy, or radiotherapy alone
Study: 9324434
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of D5W
Study: 24615132
Drug: Mass azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mass azithromycin treatment (once-treated communities)
Study: 24615132
Drug: Mass azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mass azithromycin treatment (twice-treated communities)
Study: 21186648
Drug: Alternating magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alternating magnetic field treatment
Study: 16641573
Drug: HAMS-ORS (50g/L)
Normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAMS-ORS (50g/L)
Study: 16641573
Drug: G-ORS (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-ORS (control)
Study: 8627205
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aerosol (25, 50, or 100 mg bid for 12 weeks)
Study: 3898416
Drug: Combined steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined steroid and beta-stimulant preparation (salbutamol 100 micrograms/puff and beclomethasone dipropionate 50 micrograms/puff)
Study: 30098982
Drug: Prior local
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior local treatment
Study: 20535923
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose BVC (0.5 mg/kg)
Study: 20535923
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose BVC (1.0 mg/kg)
Study: 15705234
Drug: 15 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/d wolfberry (estimated to contain almost 3 mg zeaxanthin) for 28 days
Study: 10534967
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) oxycodone (administered every 12 hours)
Study: 10534967
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) oxycodone (4 times a day)
Study: 1675763
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (400 mg per kilogram of body weight) every 28 days
Study: 22383996
Drug: Cocoa+hazelnuts+phytosterols (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa+hazelnuts+phytosterols (2 g/d)
Study: 22383996
Drug: Cocoa+hazelnuts+phytosterols+soluble fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa+hazelnuts+phytosterols+soluble fiber (20 g/d)
Study: 22383996
Drug: Cocoa cream
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa cream (control)
Study: 19384121
Drug: Concurrent vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent vaginal dinoprostone (3 mg pessary) and oxytocin infusion
Study: 19384121
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion only (placebo)
Study: 17463140
Drug: LCT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCT treatment group
Study: 9576405
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy for 6 months with targeted INR of 2.0 to 2.85
Study: 9576405
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy for 6 months
Study: 9576405
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy for 6 months or indefinitely
Study: 9576405
Drug: No anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulation therapy during the follow-up period
Study: 7713766
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with 3 cycles of carboplatin/5-fluorouracil prior to surgery and radiotherapy (arm A)
Study: 10550374
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with surgery and radiotherapy (arm B)
Study: 2105793
Drug: Pituitary suppression
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pituitary suppression with buserelin followed by pure follicle stimulating hormone
Study: 346430
Drug: Cimetidine (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1.6 g per day)
Study: 23663795
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training with a load of 40% of maximal inspiratory pressure, 5 sets of 10 breaths, twice a day, 7 days a week.
Study: 8087515
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy and radiotherapy (vindesine, cyclophosphamide, cisplatin, and lomustine) with a radiation dose of 65 Gy
Study: 8087515
Drug: Radiotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy alone with a radiation dose of 65 Gy
Study: 2790539
Drug: Thymostimulin (TP‐1)
Normalized name: thymostimulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin (TP‐1) at 1 mg/kg for 14 days then weekly for 12 weeks
Study: 4633061
Drug: Twice-weekly oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly oral regimen of isoniazid plus PAS
Study: 4633061
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral regimen of isoniazid plus PAS
Study: 29172212
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 80 mg per day until the day of surgery (group 1)
Study: 29172212
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) stopped 4 days before surgery (group 2)
Study: 23001939
Drug: Catechin-rich oil
Normalized name: catechin
DrugBank: Cianidanol (DB14086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Catechin-rich oil palm leaf extract (OPLE) 0.5 g day(‐1)
Study: 17294997
Drug: Intramuscular 1
Normalized name: Zyprexa IntraMuscular 10mg Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 1 mg/kg tramadol
Study: 17294997
Drug: Intramuscular 1
Normalized name: Zyprexa IntraMuscular 10mg Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 1 mg/kg meperidine
Study: 17294997
Drug: Intramuscular 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 0.5 mg/kg ketamine
Study: 10377734
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with interferon-alpha-2b (3 MU, three times a week) and ribavirin (1000-1200 mg daily) for one year
Study: 10377734
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with interferon-alpha-2b and ribavirin
Study: 8927233
Drug: Amantadine (AMA)
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine (AMA) 100 mg, tid
Study: 8927233
Drug: Biperiden (BIP)
DrugBank: Biperiden (DB00810)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biperiden (BIP) 2 mg, tid
Study: 1712193
Drug: Moricizine 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moricizine 750 mg/day
Study: 1712193
Drug: Disopyramide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide 600 mg/day
Study: 7112396
Drug: Preoperative intralymphatic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative intralymphatic immunotherapy with MER-BCG, surgical excision with regional lymphadenectomy, and postoperative monthly intradermal vaccinations with BCG
Study: 30522922
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (1.8 mg/kg) + cyclophosphamide (750 mg/m2) + doxorubicin (50 mg/m2) + prednisone (100 mg) (A+CHP)
Study: 30522922
Drug: Cyclophosphamide (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (750 mg/m2) + doxorubicin (50 mg/m2) + vincristine (1.4 mg/m2) + prednisone (100 mg) (CHOP)
Study: 25106776
Drug: Topical Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Steroid (S)
Study: 16117818
Drug: r‐HuEPO (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO (50 U/kg, administered three times a week for 25 days)
Study: 12191566
Drug: 25mg TNFR:Fc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg TNFR:Fc administered twice a week for 10 weeks
Study: 10192108
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation (enteric coated capsule containing 90 mg peppermint oil and 50 mg caraway oil)
Study: 10192108
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (enteric soluble formulation containing 36 mg peppermint oil and 20 mg caraway oil)
Study: 10192108
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation
Study: 7766746
Drug: Ispaghula, 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ispaghula, 3.5 g twice a day
Study: 7766746
Drug: Vancomycin, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin, 250 mg t.d.s. per os
Study: 1361068
Drug: Salmeterol 100
Normalized name: fluticasone-salmeterol 100 mcg-50 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 100 micrograms twice daily
Study: 29870855
Drug: PCT-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT-guided therapy (n=275)
Study: 22541305
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) as an adjunct to eccentric exercises
Study: 22541305
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment as an adjunct to eccentric exercises
Study: 19074534
Drug: MDMA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (100 mg) with ethanol (0.6 per thousand)
Study: 19074534
Drug: MDMA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (100 mg) alone
Study: 7859051
Drug: Bendroflumethiazide 2.5-5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide 2.5-5.0 mg
Study: 12526280
Drug: Enalapril 10-20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10-20 mg
Study: 8453855
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg twice a day)
Study: 2698934
Drug: Nifedipine +
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine + Chlorthalidone (both at the same doses)
Study: 779554
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate 0.1 mg per kg
Study: 30768766
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily subcutaneous semaglutide
Study: 30768766
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily 3.0 mg liraglutide
Study: 17290039
Drug: Fluticasone 500
Normalized name: FLUTICASONE 500MCG/SALMETEROL 50MCG INHL,ORAL,DISKUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone 500 microg, twice a day
Study: 10365628
Drug: Social Support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Support Questionnaire (SSQ) administered to psychiatric patients
Study: 10365628
Drug: Social Support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Support Questionnaire (SSQ) administered to healthy controls
Study: 8896396
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF; 5 micrograms/kg) plus stem cell factor (SCF; 20 micrograms/kg) after chemotherapy
Study: 8896396
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and G-CSF alone
Study: 7095850
Drug: 25 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 micrograms of both polysaccharides premixed in a single injection
Study: 29347874
Drug: Hydrocortisone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (200 mg per day)
Study: 25179916
Drug: RCT-18 (1.2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT-18 (1.2, 6, 18, 60, 180, 360, 540 mg)
Study: 25179916
Drug: RCT-18 (540
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT-18 (540 mg)
Study: 25179916
Drug: RCT-18 (180,
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT-18 (180, 360, 540 mg)
Study: 15646430
Drug: Dioctahedral smectite
Normalized name: Dioctahedral smectite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dioctahedral smectite (3 g, three sachets, administered 1 h after meals for 28 days)
Study: 15646430
Drug: Probiotic preparation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic preparation (Bifico 210 mg, two capsules for 28 days)
Study: 7925518
Drug: Nisoldipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (20 mg once daily, n = 16)
Study: 2511299
Drug: Usual dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual dosage of lithium
Study: 2511299
Drug: Reduced lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced lithium dosage by up to 50%
Study: 25561281
Drug: Blood Purification
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood Purification (BP) treatment
Study: 23116458
Drug: 3.6 mg
Normalized name: menthol 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mg MSF
Study: 23116458
Drug: 7.2 mg
Normalized name: lysine 7.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.2 mg MSF
Study: 23116458
Drug: 10.8 mg
Normalized name: goserelin 10.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.8 mg MSF
Study: 19922132
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rhEPO) 40,000 units, administered fortnightly for 24 months
Study: 16508590
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of olmesartan medoxomil once daily
Study: 10661334
Drug: Chemotherapy before
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy before or after irradiation (n = 40 before, n = 15 after)
Study: 9339690
Drug: Pramipexole (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (up to 4.5 mg per day)
Study: 9339690
Drug: Bromocriptine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (30 mg per day)
Study: 8348063
Drug: Beta-carotene, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene, 30 mg/day
Study: 24312194
Drug: HIV‐DNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV‐DNA vaccine in addition to ongoing antiretroviral treatment (ART) (Group B)
Study: 24312194
Drug: Ongoing antiretroviral
Normalized name: Ongo-Fin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing antiretroviral treatment (ART) (Group A)
Study: 18432528
Drug: High-dose polyestradiol
Normalized name: POLYESTRADIOL
DrugBank: Polyestradiol phosphate (DB09369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose polyestradiol phosphate (PEP; Estradurin) 240 mg i.m. twice a month for 2 months and thereafter monthly
Study: 18432528
Drug: Combined androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined androgen deprivation (CAD) with flutamide (Eulexin) 250 mg t.i.d. and triptorelin (Decapeptyl) 3.75 mg i.m. per month or bilateral orchidectomy
Study: 12854267
Drug: Calcium ascorbate
Normalized name: Calcium Ascorbate
DrugBank: Calcium ascorbate (DB14483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium ascorbate (1 gram daily for 14 +/- 3 days)
Study: 12854267
Drug: Placebo (identically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identically looking tablets)
Study: 8561070
Drug: n‐3 polyunsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 polyunsaturated fatty acid‐rich fish oil supplement for 21 days
Study: 8561070
Drug: n‐3 polyunsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 polyunsaturated fatty acid‐rich fish oil supplement with interferon‐gamma incubation
Study: 1907839
Drug: Pravastatin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin with propranolol (40 mg twice daily)
Study: 1907839
Drug: Lovastatin with
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin with propranolol (40 mg twice daily)
Study: 28077530
Drug: Maize-derived HES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maize-derived HES solution
Study: 28077530
Drug: Potato-derived HES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potato-derived HES solution
Study: 19008724
Drug: moxonidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: moxonidine (0.3 mg twice daily)
Study: 19008724
Drug: atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (50 mg once daily)
Study: 15953083
Drug: Moisturizing cream
Normalized name: MOISTURIZING CREAM
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizing cream applied twice daily for 6 weeks
Study: 3909132
Drug: i.m. morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. morphine (4, 8 and 16 mg)
Study: 30834812
Drug: Unilateral hybrid
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral hybrid therapy (UHT; unilateral robot‐assisted therapy + modified constraint‐induced movement therapy)
Study: 30834812
Drug: Bilateral hybrid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral hybrid therapy (BHT; bilateral robot‐assisted therapy + bilateral arm training)
Study: 30834812
Drug: Robot therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot therapy (RT)
Study: 29423521
Drug: Sym004, 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym004, 12 mg/kg/wk (arm A)
Study: 29423521
Drug: Sym004, 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym004, 9 mg/kg loading dose followed by 6 mg/kg/wk (arm B)
Study: 29423521
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice of treatment (arm C)
Study: 26813548
Drug: β-blocker (BB)
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blocker (BB) treatment (any molecule and any dose)
Study: 26813548
Drug: Non-BB treatment
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-BB treatment
Study: 25100236
Drug: rosuvastatin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin (5 or 2.5 mg/day)
Study: 22883585
Drug: Heparin gelatin
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin gelatin sponge stickers
Study: 21059972
Drug: Twice-a-week supervised
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-week supervised aerobic and resistance training plus structured exercise counseling
Study: 9095400
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride 300 mg twice daily
Study: 27680049
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy associated with Essential Fatty Acids
Study: 20189659
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5mg/kg of 2% lidocaine)
Study: 18925883
Drug: Cumulative received
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative received vaccine doses
Study: 16687966
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with amlodipine besylate/benazepril hydrochloride 5/20 mg
Study: 16687966
Drug: Benazepril hydrochloride
Normalized name: Benazepril Hydrochloride
DrugBank: Benazepril (DB00542)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benazepril hydrochloride 20 mg
Study: 11075844
Drug: Almotriptan (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan (both doses)
Study: 22722501
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER (6-9 mg/d)
Study: 22722501
Drug: Oral Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Olanzapine (10-15 mg/d)
Study: 19720897
Drug: Pemetrexed-carboplatin (pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed-carboplatin (pemetrexed 500 mg/m² on day 1; carboplatin AUC 5 on day 1)